SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that it plans to expand its commercial presence by adding approximately 150 sales representatives to its current selling efforts to promote ZEGERID® brand immediate-release omeprazole products in the U.S. To facilitate the expansion, the company intends to enter into an agreement with a contract sales organization during the fourth quarter of 2006 and expects the new sales representatives to be trained and in place by the end of the first quarter of 2007.
